Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H44N4O4S |
| Molecular Weight | 484.696 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)NC[C@H]2CC[C@H](N)CC2)C(C)(C)SC(C)C
InChI
InChIKey=MNMZVSQUWOILCZ-MUGJNUQGSA-N
InChI=1S/C24H44N4O4S/c1-6-14-32-23(31)27-20(24(4,5)33-16(2)3)22(30)28-13-7-8-19(28)21(29)26-15-17-9-11-18(25)12-10-17/h16-20H,6-15,25H2,1-5H3,(H,26,29)(H,27,31)/t17-,18-,19-,20-/m0/s1
| Molecular Formula | C24H44N4O4S |
| Molecular Weight | 484.696 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Mitsubishi Tanabe Pharma was developing Sofigatran, a thrombin inhibitor, for the treatment of deep vein thrombosis. Sofigatran, is a direct oral thrombin inhibitor with a competitive binding mechanism. It has been assessed in a phase II trial for the treatment of deep vein thrombosis The compound was in phase II clinical trial for the treatment of DVT. Results of this trial have not been published and the clinical development of sofigatran has been discontinued by Mitsubishi Tanabe Pharma in 2007.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:45:59 GMT 2023
by
admin
on
Fri Dec 15 18:45:59 GMT 2023
|
| Record UNII |
5X6P105U1Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152382
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
300000037023
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
8751
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
5X6P105U1Y
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
187602-11-5
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
DTXSID50940225
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
